Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available.
Calidi Biotherapeutics, Inc. has entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. to sell 5,000,000 shares of its common stock at $0.85 per share in a public offering, expected to close on January 10, 2025. This offering is projected to generate gross proceeds of $4.25 million. The agreement includes restrictions on further stock issuance for a specified period and involves lock-up agreements for company insiders. The Placement Agent will receive an 8% cash fee and a 1% management fee from the proceeds, along with warrants for additional shares. The offering aligns with the company’s strategy to strengthen its financial position within the market.
More about Calidi Biotherapeutics
YTD Price Performance: 14.41%
Average Trading Volume: 1,797,447
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $25.44M
For an in-depth examination of CLDI stock, go to TipRanks’ Stock Analysis page.
